Genetic variation in the insulin, insulin-like growth factor, growth hormone, and leptin pathways in relation to breast cancer in African-American women: the AMBER consortium

The insulin/insulin-like growth factor (IGF) system and related pathways such as growth hormone, and leptin signaling have a key role in cancer development. It is unclear how germline variation in these pathways affects breast cancer risk. We conducted gene-based analyses of 184 genes in the insulin/IGF, growth hormone, and leptin pathways to identify genetic variation associated with risk of breast cancer overall, and for estrogen receptor (ER) subtypes. Tag single-nucleotide polymorphisms (SNPs) for each gene were selected and genotyped on a customized Illumina SNP array. Imputation was carried out using 1000 Genomes haplotypes. The analysis included 91,627 SNPs genotyped or imputed in 3,663 breast cancer cases, (1,983 ER-positive and 1,098 ER-negative) and 4,687 controls from the African American Breast Cancer Epidemiology and Risk consortium, a collaborative project of four large studies of breast cancer in African-American women (Carolina Breast Cancer Study, Black Women's Health Study, Women's Circle of Health Study, and Multiethnic Cohort). We used a multi-locus adaptive joint test to determine the association of each gene with overall breast cancer and ER subtypes. The most significant gene associations (P⩽0.01) were BAIAP2 and CALM2 for overall breast cancer; BAIAP2 and CSNK2A1 for ER+ breast cancer; and BRAF, BAD, and MAPK3 for ER− breast cancer. The association of BAD with ER− breast cancer was explained by a two-SNP risk model; all other associations were best explained by one-SNP risk models. In total, six genes and seven SNPs had suggestive associations with overall breast cancer or ER subtypes in African-American women.

[1]  P. Newcomb,et al.  Prolactin and growth hormone levels in premenopausal women with breast cancer and healthy women with a strong family history of breast cancer , 1991, Cancer.

[2]  J. Palmer,et al.  The Black Women's Health Study: a follow-up study for causes and preventions of illness. , 1995, Journal of the American Medical Women's Association.

[3]  R. Roth,et al.  Characterization and Cloning of a 58/53-kDa Substrate of the Insulin Receptor Tyrosine Kinase (*) , 1996, The Journal of Biological Chemistry.

[4]  G. Nuovo,et al.  Hyperexpression of mitogen-activated protein kinase in human breast cancer. , 1997, The Journal of clinical investigation.

[5]  O. Bachs,et al.  New nuclear functions for calmodulin. , 1998, Cell calcium.

[6]  David J Hunter,et al.  Circulating concentrations of insulin-like growth factor I and risk of breast cancer , 1998, The Lancet.

[7]  J R Marshall,et al.  Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. , 2000, American journal of epidemiology.

[8]  D O Stram,et al.  A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics. , 2000, American journal of epidemiology.

[9]  L. Kindblom,et al.  Growth hormone receptor is expressed in human breast cancer. , 2001, The American journal of pathology.

[10]  M. Raccurt,et al.  High stromal and epithelial human gh gene expression is associated with proliferative disorders of the mammary gland. , 2002, The Journal of endocrinology.

[11]  R. Millikan,et al.  The Carolina Breast Cancer Study: integrating population-based epidemiology and molecular biology , 1995, Breast Cancer Research and Treatment.

[12]  F. Clavel-Chapelon,et al.  Body size and breast cancer risk: Findings from the European prospective investigation into cancer and nutrition (EPIC) , 2004, International journal of cancer.

[13]  M. Bouxsein,et al.  Inhibition of growth hormone action improves insulin sensitivity in liver IGF-1-deficient mice. , 2004, The Journal of clinical investigation.

[14]  M. Takamura,et al.  Overexpression of extracellular signal‐regulated protein kinase and its correlation with proliferation in human hepatocellular carcinoma , 2004, Liver international : official journal of the International Association for the Study of the Liver.

[15]  H. Nagawa,et al.  Enhanced Expression of Leptin and Leptin Receptor (OB-R) in Human Breast Cancer , 2004, Clinical Cancer Research.

[16]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[17]  D. Hunter,et al.  Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II. , 2006, Endocrine-related cancer.

[18]  C. González,et al.  The European Prospective Investigation into Cancer and Nutrition (EPIC) , 2004, Public Health Nutrition.

[19]  D. Reich,et al.  Population Structure and Eigenanalysis , 2006, PLoS genetics.

[20]  K. Hemminki,et al.  The GH1/IGF-1 axis polymorphisms and their impact on breast cancer development , 2007, Breast Cancer Research and Treatment.

[21]  F Berrino,et al.  IGF-I, IGFBP-3 and breast cancer risk in women: The European Prospective Investigation into Cancer and Nutrition (EPIC). , 2006, Endocrine-related cancer.

[22]  A. Russo,et al.  Increased Expression of Leptin and the Leptin Receptor as a Marker of Breast Cancer Progression: Possible Role of Obesity-Related Stimuli , 2006, Clinical Cancer Research.

[23]  B. Henderson,et al.  Genetic determinants of circulating insulin-like growth factor (IGF)-I, IGF binding protein (BP)-1, and IGFBP-3 levels in a multiethnic population. , 2007, The Journal of clinical endocrinology and metabolism.

[24]  D. English,et al.  Circulating Insulin-Like Growth Factor-I and Binding Protein-3 and the Risk of Breast Cancer , 2007, Cancer Epidemiology Biomarkers & Prevention.

[25]  D. Albanes,et al.  Adiposity, adult weight change, and postmenopausal breast cancer risk. , 2006, Archives of internal medicine.

[26]  Manuel A. R. Ferreira,et al.  PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.

[27]  M. Schulze,et al.  Findings from the European Prospective Investigation Into Cancer and Nutrition (EPIC)-Potsdam Study , 2008 .

[28]  Giorgio Scita,et al.  IRSp53: crossing the road of membrane and actin dynamics in the formation of membrane protrusions. , 2008, Trends in cell biology.

[29]  M. Pike,et al.  IGF-1, IGFBP-1, and IGFBP-3 Polymorphisms Predict Circulating IGF Levels but Not Breast Cancer Risk: Findings from the Breast and Prostate Cancer Cohort Consortium (BPC3) , 2008, PloS one.

[30]  F. Schmidt.  Meta-Analysis , 2008 .

[31]  P. Donnelly,et al.  A Flexible and Accurate Genotype Imputation Method for the Next Generation of Genome-Wide Association Studies , 2009, PLoS genetics.

[32]  H. Valdimarsdottir,et al.  Conducting Molecular Epidemiological Research in the Age of HIPAA: A Multi-Institutional Case-Control Study of Breast Cancer in African-American and European-American Women , 2009, Journal of oncology.

[33]  O. Filhol,et al.  Protein Kinase CK2 in Health and Disease , 2009, Cellular and Molecular Life Sciences.

[34]  H. Jernström,et al.  IGFBP1 and IGFBP3 polymorphisms predict circulating IGFBP-3 levels among women from high-risk breast cancer families , 2011, Breast Cancer Research and Treatment.

[35]  M. Thun,et al.  Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium. , 2010, Human molecular genetics.

[36]  W. Willett,et al.  Eighteen insulin-like growth factor pathway genes, circulating levels of IGF-I and its binding protein, and risk of prostate and breast cancer. , 2010, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[37]  C. McCarty,et al.  Circulating Insulin-like Growth Factor (IGF)-I and IGF Binding Protein (IGFBP)-3 Levels and Postmenopausal Breast Cancer Risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) Cohort , 2010, Hormones & cancer.

[38]  D. Leroith,et al.  Biological effects of growth hormone on carbohydrate and lipid metabolism. , 2010, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[39]  Michael Krawczak,et al.  Genome-wide association study for colorectal cancer identifies risk polymorphisms in German familial cases and implicates MAPK signalling pathways in disease susceptibility. , 2010, Carcinogenesis.

[40]  Andrew W Roddam,et al.  Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies , 2010, The Lancet. Oncology.

[41]  Federica Madia,et al.  Growth Hormone Receptor Deficiency Is Associated with a Major Reduction in Pro-Aging Signaling, Cancer, and Diabetes in Humans , 2011, Science Translational Medicine.

[42]  S. Morimura,et al.  Rac1 and Stathmin but Not EB1 Are Required for Invasion of Breast Cancer Cells in Response to IGF-I , 2011, International journal of cell biology.

[43]  P. Kraft,et al.  Leptin and leptin receptor genes in relation to premenopausal breast cancer incidence and grade in Caucasian women , 2011, Breast Cancer Research and Treatment.

[44]  R. Millikan,et al.  Common genetic variation in adiponectin, leptin, and leptin receptor and association with breast cancer subtypes , 2011, Breast Cancer Research and Treatment.

[45]  Chibo Liu,et al.  Polymorphisms in three obesity-related genes (LEP, LEPR, and PON1) and breast cancer risk: a meta-analysis , 2011, Tumor Biology.

[46]  Niels Keiding,et al.  Quantifying Mediating Effects of Endogenous Estrogen and Insulin in the Relation between Obesity, Alcohol Consumption, and Breast Cancer , 2012, Cancer Epidemiology, Biomarkers & Prevention.

[47]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[48]  A. Olshan,et al.  A collaborative study of the etiology of breast cancer subtypes in African American women: the AMBER consortium , 2013, Cancer Causes & Control.

[49]  Shirley L. Campbell,et al.  ARF1 controls Rac1 signaling to regulate migration of MDA-MB-231 invasive breast cancer cells. , 2013, Cellular signalling.

[50]  Yurii B. Shvetsov,et al.  Prediagnostic Leptin, Adiponectin, C-Reactive Protein, and the Risk of Postmenopausal Breast Cancer , 2013, Cancer Prevention Research.

[51]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[52]  C. Ambrosone,et al.  Rethinking sources of representative controls for the conduct of case–control studies in minority populations , 2013, BMC Medical Research Methodology.

[53]  Jaana M. Hartikainen,et al.  Large-scale genotyping identifies 41 new loci associated with breast cancer risk , 2013, Nature Genetics.

[54]  Liqin Wang,et al.  The Association between Leptin Level and Breast Cancer: A Meta-Analysis , 2013, PloS one.

[55]  Faming Liang,et al.  A fast multilocus test with adaptive SNP selection for large-scale genetic-association studies , 2013, European Journal of Human Genetics.

[56]  M. Berchtold,et al.  The many faces of calmodulin in cell proliferation, programmed cell death, autophagy, and cancer. , 2014, Biochimica et biophysica acta.

[57]  J. Lancaster,et al.  BAD-mediated apoptotic pathway is associated with human cancer development , 2015, International journal of molecular medicine.

[58]  Patrick Neven,et al.  Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer , 2015 .

[59]  T. Rohan,et al.  Breast cancer risk in metabolically healthy but overweight postmenopausal women. , 2015, Cancer research.